Related Experiment Video
Updated: Feb 19, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Can Naldemedine Allow Higher Oxycodone Dosing in Patients with Cancer? A Single-Center Retrospective Study
Shinya Kajiura1,2,3, Shingo Chikaoka2, Yuta Yagi2
1Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama, Japan.
Background:
Opioid-induced constipation (OIC) limits opioid titration in cancer care. Before the use of peripherally acting μ-opioid receptor antagonists (PAMORAs), OIC often required switching from oxycodone to lower-risk opioids, such as transdermal fentanyl. Whether naldemedine allows oxycodone escalation without switching remains unclear. We evaluated the maximum scheduled daily oxycodone dose as a surrogate for maintaining therapy without constipation-driven switching.
Methods:
We retrospectively reviewed adults with cancer pain who initiated oral oxycodone at Toyama University Hospital between June 2017 and December 2018. Patients receiving naldemedine were classified as Group A; others as Group B. The primary endpoint was the maximum scheduled controlled-release oxycodone dose during follow-up; rescue doses were excluded.
Results:
Among 217 patients, the median maximum dose was higher with naldemedine (40 mg/day [range 10-480] versus 20 mg/day [10-320]; p < 0.0001).
Conclusions:
Naldemedine enabled higher oxycodone dosing, suggesting OIC management reduces opioid switching.
Related Concept Videos
Drug Dosing: Obese Patients
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Drug Dosing: Geriatric Patients
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
